Cochrane Abstracts
First‐line therapy for high‐risk people with chronic lymphocytic leukemia: a network meta‐analysis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"First‐line Therapy for High‐risk People With Chronic Lymphocytic Leukemia: a Network Meta‐analysis." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/440712/all/First‐line_therapy_for_high‐risk_people_with_chronic_lymphocytic_leukemia:_a_network_meta‐analysis.
First‐line therapy for high‐risk people with chronic lymphocytic leukemia: a network meta‐analysis. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440712/all/First‐line_therapy_for_high‐risk_people_with_chronic_lymphocytic_leukemia:_a_network_meta‐analysis. Accessed March 26, 2025.
First‐line therapy for high‐risk people with chronic lymphocytic leukemia: a network meta‐analysis. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440712/all/First‐line_therapy_for_high‐risk_people_with_chronic_lymphocytic_leukemia:_a_network_meta‐analysis
First‐line Therapy for High‐risk People With Chronic Lymphocytic Leukemia: a Network Meta‐analysis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/440712/all/First‐line_therapy_for_high‐risk_people_with_chronic_lymphocytic_leukemia:_a_network_meta‐analysis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - First‐line therapy for high‐risk people with chronic lymphocytic leukemia: a network meta‐analysis
ID - 440712
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/440712/all/First‐line_therapy_for_high‐risk_people_with_chronic_lymphocytic_leukemia:_a_network_meta‐analysis
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
